Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KY 0118

Next Previous
X
Search
Drug Profile

KY 0118

Alternative Names: KY-0118

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novatim Immune Therapeutics (Zhejiang)
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 2 replacements; Programmed cell death 1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 28 Aug 2024 Novatim Immune Therapeutics (Zhejiang) files an IND application for Solid tumours (Late-stage disease; Combination therapy) in China and the US, before August 2024 (Novatim Immune Therapeutics (Zhejiang) pipeline, August 2024)
  • 28 Aug 2024 Novatim Immune Therapeutics (Zhejiang) files an IND application for Solid tumours (Late-stage disease; Monptherapy) in the US, before August 2024 (Novatim Immune Therapeutics (Zhejiang) pipeline, August 2024)
  • 31 May 2024 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top